285 related articles for article (PubMed ID: 7621254)
1. Antisense approaches to cancer gene therapy.
Mercola D; Cohen JS
Cancer Gene Ther; 1995 Mar; 2(1):47-59. PubMed ID: 7621254
[TBL] [Abstract][Full Text] [Related]
2. Applications of antisense oligonucleotides in oncology.
Pierga JY; Magdelenat H
Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):237-61. PubMed ID: 7920172
[TBL] [Abstract][Full Text] [Related]
3. [Prospects for antisense therapy].
Maekawa T
Rinsho Ketsueki; 1995 May; 36(5):410-8. PubMed ID: 7783344
[TBL] [Abstract][Full Text] [Related]
4. Tissue distribution of liposome-mediated epidermal growth factor receptor antisense gene therapy.
Thomas SM; Zeng Q; Dyer KF; Suscovich TJ; Kanter PM; Whalen JD; Watkins SF; Grandis JR
Cancer Gene Ther; 2003 Jul; 10(7):518-28. PubMed ID: 12833132
[TBL] [Abstract][Full Text] [Related]
5. Anti-oncogene and tumor suppressor gene therapy--examples from a lung cancer animal model.
Zhang WW; Roth JA
In Vivo; 1994; 8(5):755-69. PubMed ID: 7727723
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic potential of antisense oligonucleotides.
Sharma HW; Narayanan R
Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
[TBL] [Abstract][Full Text] [Related]
7. Oligonucleotide therapeutics: clothing the emperor.
Gewirtz AM
Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA.
Kondo S; Kondo Y; Li G; Silverman RH; Cowell JK
Oncogene; 1998 Jun; 16(25):3323-30. PubMed ID: 9681832
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of proliferation by c-myb antisense RNA and oligodeoxynucleotides in transformed neuroectodermal cell lines.
Raschellà G; Negroni A; Skorski T; Pucci S; Nieborowska-Skorska M; Romeo A; Calabretta B
Cancer Res; 1992 Aug; 52(15):4221-6. PubMed ID: 1638535
[TBL] [Abstract][Full Text] [Related]
10. Preclinical study on gene therapy of cervical carcinoma using adeno-associated virus vectors.
Kunke D; Grimm D; Denger S; Kreuzer J; Delius H; Komitowski D; Kleinschmidt JA
Cancer Gene Ther; 2000 May; 7(5):766-77. PubMed ID: 10830724
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines.
Lee CT; Wu S; Gabrilovich D; Chen H; Nadaf-Rahrov S; Ciernik IF; Carbone DP
Cancer Res; 1996 Jul; 56(13):3038-41. PubMed ID: 8674059
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides.
Cucco C; Calabretta B
Cancer Res; 1996 Oct; 56(19):4332-7. PubMed ID: 8813118
[TBL] [Abstract][Full Text] [Related]
13. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
Oberbauer R
Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
[TBL] [Abstract][Full Text] [Related]
14. [Basics of antisense oligonucleotide therapy and current therapeutical strategies in urology].
Kausch I; Böhle A
Aktuelle Urol; 2003 Dec; 34(7):458-68. PubMed ID: 14655082
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of tumor growth in liver epithelial cells transfected with a transforming growth factor alpha antisense gene.
Laird AD; Brown PI; Fausto N
Cancer Res; 1994 Aug; 54(15):4224-32. PubMed ID: 8033155
[TBL] [Abstract][Full Text] [Related]
16. Antisense oligodeoxynucleotides targeted against different regions of cyclin D1 mRNA may exert different inhibitory effects on cell growth and gene expression.
Hung WC; Huang JS; Chuang LY
Biochem Biophys Res Commun; 1996 Mar; 220(3):719-23. PubMed ID: 8607831
[TBL] [Abstract][Full Text] [Related]
17. Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo.
Kang CS; Zhang ZY; Jia ZF; Wang GX; Qiu MZ; Zhou HX; Yu SZ; Chang J; Jiang H; Pu PY
Cancer Gene Ther; 2006 May; 13(5):530-8. PubMed ID: 16410821
[TBL] [Abstract][Full Text] [Related]
18. Ki-67-directed antisense therapy in an orthotopic renal cell carcinoma model.
Kausch I; Jiang H; Brocks C; Bruderek K; Krüger S; Sczakiel G; Jocham D; Böhle A
Eur Urol; 2004 Jul; 46(1):118-24; discussion 124-5. PubMed ID: 15183557
[TBL] [Abstract][Full Text] [Related]
19. Ribosomal protein P2: a potential molecular target for antisense therapy of human malignancies.
Gardner-Thorpe J; Ito H; Ashley SW; Whang EE
Anticancer Res; 2003; 23(6C):4549-60. PubMed ID: 14981896
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotide technology in the development of cancer therapeutics.
Tseng BY; Brown KD
Cancer Gene Ther; 1994 Mar; 1(1):65-71. PubMed ID: 7621240
[No Abstract] [Full Text] [Related]
[Next] [New Search]
